Standard BioTools Inc. (LAB) News
Filter LAB News Items
LAB News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
LAB News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest LAB News From Around the Web
Below are the latest news stories about STANDARD BIOTOOLS INC that investors may wish to consider to help them evaluate LAB as an investment opportunity.
Standard BioTools SomaScan Assay Powers Key Insights into Semaglutide Treatment Published in Nature MedicineNovo Nordisk initiated study validates the power of proteomics to provide unique insights into mechanisms of action and expanded drug indications as well as the potential for shorter and smaller clinical trialsSOUTH SAN FRANCISCO, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company”) announced today that its SomaScan™ Platform played a pivotal role in a study published in the current issue of Nature Medicine titled “Proteomic changes upon treatment with s |
In the wake of Standard BioTools Inc.'s (NASDAQ:LAB) latest US$56m market cap drop, institutional owners may be forced to take severe actionsKey Insights Given the large stake in the stock by institutions, Standard BioTools' stock price might be vulnerable to... |
Standard BioTools to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceSOUTH SAN FRANCISCO, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced its President and Chief Executive Officer, Michael Egholm, PhD, will present at the upcoming 43rd Annual J.P. Morgan Healthcare Conference taking place on January 13th - 16th at the Westin St. Francis Hotel in San Francisco, CA. Dr. Egholm’s corporate presentation will be held on January 16th, 2024, at 9:45 a.m. PT. A live audio webcast will be available to investors and other inte |
Standard BioTools Appoints Alex Kim as Chief Financial OfficerSOUTH SAN FRANCISCO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (“Standard BioTools” or the “Company”) (Nasdaq: LAB) today announced the appointment of Alex Kim as Chief Financial Officer, effective November 11, 2024. Kim, a co-founder and most recently Chief Operating Officer of Standard BioTools, brings nearly 30 years of financial and operations experience in the healthcare and life sciences industries to the role and will oversee Standard BioTools’ finance organization. |
Earnings Release: Here's Why Analysts Cut Their Standard BioTools Inc. (NASDAQ:LAB) Price Target To US$3.17A week ago, Standard BioTools Inc. ( NASDAQ:LAB ) came out with a strong set of third-quarter numbers that could... |
Standard BioTools Third Quarter 2024 Earnings: Beats ExpectationsStandard BioTools ( NASDAQ:LAB ) Third Quarter 2024 Results Key Financial Results Revenue: US$45.0m (up 77% from 3Q... |
Standard BioTools Inc (LAB) Q3 2024 Earnings Call Highlights: Navigating Market Challenges with ...Despite a decline in overall revenue, Standard BioTools Inc (LAB) shows resilience with strong consumables growth and improved operational efficiencies. |
Standard BioTools to Participate in Upcoming Investor ConferencesSOUTH SAN FRANCISCO, Calif., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that its management team will participate in the following investor conferences in the month of November: UBS Global Healthcare Conference on November 12th, 2024President and CEO, Michael Egholm, PhD, will participate in a corporate presentation on Tuesday, November 12, 2024, at 1:15 p.m. PTJefferies London Healthcare Conference on November 19th – 21st, 2024President and CEO, Micha |
Standard BioTools (LAB) Reports Q3 Loss, Tops Revenue EstimatesStandard BioTools (LAB) delivered earnings and revenue surprises of 37.50% and 7.07%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock? |
Standard BioTools: Q3 Earnings SnapshotLAB) on Wednesday reported a loss of $26.9 million in its third quarter. On a per-share basis, the South San Francisco, California-based company said it had a loss of 7 cents. Losses, adjusted for stock option expense and restructuring costs, were 5 cents per share. |